Harlan Contract Research Services Cytotest Cell Research Selected for Membership in EU-NETVAL
News Aug 12, 2013
EU-NETVAL provides support for the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) to develop methods to reduce, refine or replace animals used for scientific purposes.
“Being in the initial group of laboratories acknowledges the expertise of our scientists as well as our continuous work in and support for alternative in vitro methodologies, including our participation in EU validation projects in the past,” said Dr. Albrecht Poth, deputy managing director and scientific advisor for Harlan CRS Cytotest Cell Research. “We are honored to have Harlan CRS play a role in this important research evolution.”
The aim of EURL ECVAM is to promote the scientific and regulatory acceptance of non-animal tests and to coordinate the independent evaluation of tests for specific purposes. Harlan CRS Cytotest Cell Research will contribute to the development of guidance documents, procedures, training materials and collaboration tools that facilitate the development, validation and acceptance of alternative methods.
Harlan CRS began as a regional provider of research models and services in the Midwestern U.S. more than 70 years ago and today is a global provider of those services.
“We have been researching new test systems in the fields of alternative toxicology, medical devices and genetic toxicology for several years,” Dr. Poth said. “Our hope is that someday we can eliminate animal testing entirely.”
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018